Presentation of Biovitrum's Interim Report January - June, 2010
(Thomson Reuters ONE) -
The Interim Report for the second quarter 2010 will be published around 8.30
a.m. (CET) July 20.
The Swedish Orphan Biovitrum AB (publ)´s Interim Report for the second quarter
2010 will be presented by Swedish Orphan Biovitrum´s CEO Martin Nicklasson and
CFO Göran Arvidson at a media and analyst telephone conference the same day. The
presentation will be held in English and can also be followed, direct or
retrospectively, by an audio cast via internet.
Time: Tuesday, July 20, 2010 at 3 p.m. (CET)
Telephone conference call:
To participate in the Telephone Conference please call:
UK: +44 (0)207 509 5139
SWE: +46 (0)8 505 202 70
US: +1 718 354 1226
To follow the Telephone conference via audio cast, direct or retrospectively
through internet you will find the link on our web site, please visit:
www.sobi.com
The presentation material will be available on our web site 30 minutes prior to
the telephone conference, please visit: www.sobi.com
Welcome!
Erik Kinnman, EVP, Head of Investor Relations & Public Affairs
Phone: +46 8 697 21 50,erik.kinnman(at)sobi.com
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical
company with an international market presence. The company is focused on
providing and developing specialist pharmaceuticals for rare disease patients
with high medical needs. The portfolio consists of about 60 marketed products
and an emerging late stage clinical development pipe-line. Our focus areas are:
hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer
supportive care and inherited metabolic disorders. Swedish Orphan Biovitrum had
pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The
head office is located in Sweden and the share (STO: SOBI) is listed on NASDAQ
OMX Stockholm. For more information please visitwww.sobi.com.
[HUG#1431206]
Press Release July 13, 2010: http://hugin.info/134557/R/1431206/377725.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 13.07.2010 - 10:01 Uhr
Sprache: Deutsch
News-ID 23815
Anzahl Zeichen: 0
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 235 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Presentation of Biovitrum's Interim Report January - June, 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
